Linda N. Casillas

发表

Catalytic in vivo protein knockdown by small-molecule PROTACs.

I. E. Smith, Marcus Bantscheff, Kristoffer Famm, 2015, Nature chemical biology.

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.

Philip Hardwicke, John Bertin, Bryan W King, 2015, Bioorganic & medicinal chemistry.

Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Joseph P. Romano, N. C. Goodwin, J. Bertin, 2019, ACS medicinal chemistry letters.

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era

Helen T. Smith, Jipan Xie, E. Wu, 2020, Kidney medicine.

The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling.

J. Bertin, C. Sasakawa, D. Philpott, 2014, Cell host & microbe.

N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part

D. Demarini, D. Brooks, N. Laping, 2008, Journal of Pharmacology and Experimental Therapeutics.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[ d]thiazol-5-ylamino)-6-( tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, M. Convery, 2019, Journal of medicinal chemistry.

GSK1016790A, a Novel and Potent TRPV4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I

D. Demarini, D. Brooks, N. Laping, 2008 .

Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound

T. Ernest, N. Goyal, G. Koh, 2018, The AAPS Journal.

RIP3 induces apoptosis independent of pronecrotic kinase activity.

Kenta Moriwaki, Viera Kasparcova, John Bertin, 2014, Molecular cell.

Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults

Linda N. Casillas, Rajendra P. Singh, Shashidhar Joshi, 2018, Journal of acquired immune deficiency syndromes.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, D. Lipshutz, 2019 .

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.

Carol A. Capriotti, J. Bertin, M. Convery, 2016, Journal of medicinal chemistry.

An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart Failure

H. Alsaid, W. Bao, R. Willette, 2012, Science Translational Medicine.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

J. Bertin, M. Convery, D. Lipshutz, 2018, ACS medicinal chemistry letters.

Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2

W. Bao, D. Behm, S. Nerurkar, 2008, Journal of Pharmacology and Experimental Therapeutics.

Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound

T. Ernest, N. Goyal, G. Koh, 2018, The AAPS Journal.

Elicitation of disease concepts in patients with diabetic foot ulcers: a qualitative study.

V. Sikirica, Linda N. Casillas, J. Devine, 2020, Journal of wound care.

Understanding Pharmacokinetic Disconnect in Preclinical Species for 4-Aminoquinolines: Consequences of Low Permeability and High P-glycoprotein Efflux Ratio on Rat and Dog Oral Pharmacokinetics.

J. Bertin, M. Mahajan, R. Nagilla, 2020, Journal of pharmaceutical sciences.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Carol A. Capriotti, J. Bertin, M. Convery, 2018, ACS medicinal chemistry letters.